Ptc Therapeutics (PTCT) Research & Development (2012 - 2026)

Ptc Therapeutics' Research & Development history runs 15 years deep, the most recent figure standing at $100.9 million for Q1 2026.

• On a quarterly basis, Research & Development fell 7.43% year-over-year to $100.9 million in Q1 2026; TTM through Mar 2026 was $447.1 million, a 15.2% decrease from a year earlier, with the FY2025 full-year figure at $455.2 million, down 14.82% from the prior year.
• Research & Development declined to $100.9 million in Q1 2026 per PTCT's latest filing, from $133.1 million in the prior quarter.
• Across five years, Research & Development topped out at $195.1 million in Q1 2023 and bottomed at $100.2 million in Q3 2025.
• The 5-year median for Research & Development is $133.1 million (2025), against an average of $141.7 million.
• Across the five-year window, Research & Development surged 39.3% in 2023 and sank 40.48% in 2024, its largest moves.
• Year by year, Research & Development stood at $188.7 million in 2022, then slumped by 35.69% to $121.4 million in 2023, then gained by 2.82% to $124.8 million in 2024, then gained by 6.7% to $133.1 million in 2025, then declined by 24.23% to $100.9 million in 2026.
• Per Business Quant, the three latest PTCT Research & Development figures stand at $100.9 million (Q1 2026), $133.1 million (Q4 2025), and $100.2 million (Q3 2025).